An interventional study of Lycium barbarum polysaccharide and Placebo in Subthreshold Depression, Depressive Symptoms and Anxious Symptoms, sponsored by Guangzhou Psychiatric Hospital. Status unknown at 1 site in China. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-11-19.
Sponsored by Guangzhou Psychiatric Hospital · Not applicable, Interventional, and Treatment
Among 357 studies in Depression with a site in China — 118 open to participants now, 137 under way, 3 of them phase 3. Depression · China.
Among the 357 studies in Depression with a site in China, this one is the 114th largest by planned enrollment of the 283 interventional ones, is one of 17 that started in 2019, is one of 217 with no phase, and was the 87th registered.
8,577 studies on the registry are indexed under Depression; 1,720 are open to participants now.
This study's planned enrollment of 172 is above the median of 81 across 7,063 interventional studies indexed under Depression.
Browse Depression studies →118 of the 357 studies in Depression with a site in China are open now, in 12 countries. Each count lists the studies.
Of the 1,088 Depression studies recruiting now, 469 (43%) set no upper age limit and 519 (48%) stop at 75 or younger; 203 take children under 18; 310 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →357 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 17 started in 2019.
Median enrollment 132 across the 283 interventional studies, 306 across the 74 observational. Of the 140 that completed or were terminated, 9 (6%) have results posted.
20 of 357 have an industry lead sponsor. The 10 most frequent:
Guangzhou Psychiatric Hospital is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Guangzhou Psychiatric Hospital has 7 studies filed under Depression — fewer than ten, so there is no comparison to draw.
43 of the studies in Depression with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07485595Phase 3Tasly Pharmaceutical Group Co., LtdA Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression | 2026-12-31 |
| NCT07738809Capital University of Physical Education and Sports, ChinaEffects of Exercise Intervention on Sleep Quality and Emotional Problems in College Students With Depressive Symptoms | 2026-11 |
| NCT07179913The First Hospital of Jilin UniversityThe Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression | 2026-11-20 |
| NCT07247968Min SuSubanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study | 2026-11-20 |
| NCT07282366Jian-Jun OuVideo Intervention to Reduce Depression-related Stigma Among Adolescents | 2026-11-20 |
Among the 357 studies in Depression with a site in China, from their registry updates:
Lycium barbarum, a traditional Chinese herbal medicine, is a commonly used herb in the traditional Chinese pharmacopoeia . Its main active ingredient, lycium barbarum polysaccharide (LBP), is reported to have neuroprotective effects. Animal studies suggested that LBP has neuroprotective effect on optic ganglion cells. In animal models of depression, LBP can improve depressive symptom by improving synaptic plasticity. However, its clinical effect remains to be studied. We will conduct a 6-week double-blind, randomized, placebo-con-trolled trial in people with subthreshold depression.The purpose of this clinical trial is to investigate the efficacy of LBP in people with subthreshold depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental group takes LBP tablet (300mg/day) for 6 weeks
Dietary Supplement: Lycium barbarum polysaccharide
Placebo control group takes placebo 6 weeks. The placebos are the same with the LBP tablets in appearance and taste.
Dietary Supplement: Placebo
Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day)for 6 weeks
Placebo-controlled group take he placebo capsules that are identical in shape, color, and taste to LBP tablet.
Mean changes from baseline in the 21-item Hamilton Depression Rating Scale (24-HAMD)
The 24-item HAM-D scale is widely used to assess the severity of depression.The scale is a 21-item assessment used to measure depression severity. Items were rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score ranging from 0 (not at all depressed) to 64 (severely depressed).
Time frame: 6 weeks
Changes in The Screen for Child Anxiety Related Disorders (SCARED)
The SCARED is a child and parent self-report instrument used to screen for childhood anxiety disorders including general anxiety disorder, separation anxiety disorder, panic disorder, and social phobia.
Time frame: 4 and 6 weeks
Changes in sleep quality
Changes in Pittsburgh Sleep Quality Index (PSQI)
Time frame: 6 weeks
Depression severity as measured by BDI2 and Kessler Scale (K10)
The Kessler psychological distress scale (K10) is a widely used, simple self-report measure of psychological distress which can be used to identify those in need of further assessment for anxiety and depression.
Time frame: 6 weeks
Mean change from baseline in the Beck Depression Inventory-II (BDI-2)total scores
The BDI-II is a 21-item self-report measure of depressive symptom.Remission was defined as equal or less than 8 scores on BDI-2.
Time frame: 6 week
Treatment-emergent symptom side effect (TESS) scale.
Side effect was evaluated by treatment-emergent symptom side effect (TESS) scale.
Time frame: 4 and 6 weeks
Started May 2019 (actual). Primary completion is estimated for Dec 2021, 31 months after the start.
Of 3,468 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 31 months is above that.
Counting every sponsor, half of 3,566 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lycium barbarum polysaccharide
Guangzhou Psychiatric Hospital